A study on pattern of initial and acquired drug resistance for isoniazid and rifampicin in A.F.B. positive sputum smears of pulmonary tuberculosis patients at a Medical College in North Eastern Uttar Pradesh, India

Ravi K. Tiwari, Jamal Haider, Amitabh D. Shukla, Prem P. Gupta


Background: Despite availability of good quality anti-tubercular drugs and its administration through Directly Observed Therapy Short Course (DOTS) strategy of Revised National Tuberculosis Control Programme (RNTCP), tuberculosis remains a major cause of morbidity and mortality in India. The emergence of drug resistance necessitates the timely detection of susceptibility of anti-TB drugs. This can help in appropriate modification in treatment strategies.

Methods: A total of 50 patients of pulmonary TB with AFB positive sputum smears attending the OPD of TB and Chest department of B.R.D. Medical College, Gorakhpur were included. Patients were grouped based on history into new (cat-I) and previously treated patients (cat-II). Cat-II patients were further subdivided into defaulter, treatment failure and relapse groups. The culture and DST of AFB positive sputum smears of these patients was done in VersaTREK™®. At the end of study, patients were grouped according to age, sex, category and drug sensitivity pattern for Isoniazid (INH) and Rifampicin (RIF) viz mono resistance (resistance to either INH or RIF) or multi drug resistance (M.D.R.) and the resultant data were analysed.

Results: Of the total 50 patients included in this study, 18 (36%) patients were sensitive to both the drugs INH and RIF, of which 11 (22%) were of cat-I and 7 (14%) of category-II. Twenty-two (44%) patients were resistant to INH only of which 8 (16%) were of cat-I and 14 (28%) of cat-II. One (2%) case of cat-I showed resistance to RIF only, while M.D.R. type of resistance is seen in 1 (2%) patient of cat-I and 8 (16%) patients of cat-II. Pattern of resistance to both INH and RIF together (i.e. M.D.R. type) showed significant difference between cat-I and cat-II.

Conclusions: Most of the patients showing resistance to INH, RIF or both INH and RIF (M.D.R.) belonged to category-II (previously treated) patients.


DST, Isoniazid, MDR-TB, Resistance Pattern, Rifampicin

Full Text:



Palomino JC. Antibiotic Resistance and Drug Susceptibility Methods, 29th Annual Congress, Plovdiv, Bulgaria. July 2008:15-8.

Claudio P, Armando O, Luca B, Claudio S. Current Perspectives on Drug susceptibility testing of Mycobacterium tuberculosis complex: The Automated Non-radiometric systems. J of Cli Mic. Jan 2006;44(1):20-8.

TREK Diagnostic system. Thermo-Fisher Diagnostic Private Limted; Technical. Available at: Accessed 19 June 2017.

Behera D. Drug Resistant Tuberculosis in India- Is it a matter of concern? Indian J of Tuberculosis. 2007;54(3):105-9.

Paramasivan CN. An overview of drug resistant tuberculosis in India. Indian J Tuberc. 1998;45:73-81.

Tuberculosis Coalition for Technical assistance. International standards for tuberculosis care (ISTC), 2nd Ed., Tuberculosis Coalition for Technical assistance, The Hague,2009. Available at: Accessed 19 June 2017

Treatment of Tuberculosis: WHO Guidelines, 2009, 4th Edition, Geneva, World Health Organization. 2009 Available at

La Bombardi. Comparison of ESP and BACTEC system for testing susceptibilities of Mycobacterium tuberculosis complex isolates to Pyrazinamide. J. Clin. Microbiol. 2002;40:2238-9.

Angeby KA, Werngren J, Toro JC. Evaluation of BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis. Clin Microbiol infect. 2003;9:1148-52.

Scarparo C, Ricordi P, Ruggiero G. Evaluation of the fully automated BACTEC MGIT-960 system for testing susceptibilities of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampicin and ethambutol and comparison with the radiometric BACTEC 460 TB method. J. Clin Microbiol. 2004;42(3):1109-14.

Ruiz P, Zerolo FJ, Casal MJ. Comparison of Susceptibility testing of Mycobacerium tuberculosis using the ESP culture system II with that using the BACTEC method. J Clin Microbiol. 2000;38(12):4663-4.

Bergmann JS, Woods GL. Evaluation of the ESP culture system II for testing Susceptibilities of Mycobacterium tuberculosis isolates to four primary antitubercular drugs. J. Clin Microbiol. 1998;36:2940-3.

Espasa M, Salvado’ M, Vicente E, Tudo’ G, Alcaide F, Coll P et al. Evaluation of the VersaTREK system compared to the BACTEC MGIT 960 system for firstline drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2012;50(2):488-91.

WHO treatment guidelines for drug resistant tuberculosis (2016 update) (WHO/HTM/TB/2016.04). Geneva: WHO; 2016. Available at: TB guidelines2016.pdf. Accessed 19 June 2017.

Mahadev B, Jagota P, Srikantaramu N, Ganeshwaran M. Surveillance of drug resistance in Mysore district. Karnataka, NTI Bulletin. 2003;39(3,4):5-10.

Mahadev B, Kumar P, Agarwal SP, Chauhan LS and Srikantaramu N. Surveillance of drug resistance of anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. Indian J Tub. 2005;52:5-10.

Vijay S, Bala Sangameshwara VH, Jagannatha PS, Kumar P. Initial drug resistance among tuberculosis patients under DOTS programme in Bangalore city. Ind J Tub. 2004;51:17-21.

Paramasivan CN, Bhaskaran K, Venkataraman P, Chandrasekaran V, Narayanan PR. Surveillance of drug resistance in tuberculosis in the state of Tamil Nadu. Ind J Tuberc. 2000;47:27-33.

Paramasivan CN, Venkataraman P, Chandrasekaran V, Bhat S, Narayanan PR. Surveillance of drug resistance in two districts of South India. Int J Tuberc Lung Dis. 2002;6:479-84.

Rawat J, Sindhwani G, Dua RJ. Five-year trend of acquired antitubercular drug resistance in patients attending a tertiary care hospital at Dehradun (Uttarakhand). Lung India. 2009;26:106-8.